Which has higher valuation & earnings, SVRA or IVVD?

Invivyd has higher revenue and earnings than Savara. Savara is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Savara N/A N/A -$118.84M -$0.58 N/A Invivyd $53.43M 5.09 -$52.49M -$0.33 N/A

Is SVRA or IVVD more profitable?

Savara has a net margin of 0.00% compared to Invivyd's net margin of -183.90%. Invivyd's return on equity of -59.73% beat Savara's return on equity. Company Net Margins Return on Equity Return on Assets Savara N/A -90.28% -68.95% Invivyd -183.90% -59.73% -48.97%

Does the media prefer SVRA or IVVD?

In the previous week, Savara and Savara both had 1 articles in the media. Savara's average media sentiment score of 1.02 beat Invivyd's score of 0.67 indicating that Savara is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Savara 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Invivyd 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, MNKD or IVVD?

MannKind has higher revenue and earnings than Invivyd. MannKind is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MannKind $348.97M 3.08 $5.86M -$0.13 N/A Invivyd $53.43M 5.09 -$52.49M -$0.33 N/A

Is MNKD or IVVD more profitable?

MannKind has a net margin of -11.08% compared to Invivyd's net margin of -183.90%. MannKind's return on equity of -11.21% beat Invivyd's return on equity. Company Net Margins Return on Equity Return on Assets MannKind -11.08% -11.21% -6.31% Invivyd -183.90% -59.73% -48.97%

Does the media prefer MNKD or IVVD?

In the previous week, MannKind had 4 more articles in the media than Invivyd. MarketBeat recorded 5 mentions for MannKind and 1 mentions for Invivyd. Invivyd's average media sentiment score of 0.67 beat MannKind's score of 0.60 indicating that Invivyd is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MannKind 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Invivyd 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor IVVD or MLTX?

In the previous week, MoonLake Immunotherapeutics had 1 more articles in the media than Invivyd. MarketBeat recorded 2 mentions for MoonLake Immunotherapeutics and 1 mentions for Invivyd. Invivyd's average media sentiment score of 0.67 equaled MoonLake Immunotherapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Invivyd 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MoonLake Immunotherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is IVVD or JBIO more profitable?

Jade Biosciences has a net margin of 0.00% compared to Invivyd's net margin of -183.90%. Jade Biosciences' return on equity of -49.11% beat Invivyd's return on equity. Company Net Margins Return on Equity Return on Assets Invivyd -183.90% -59.73% -48.97% Jade Biosciences N/A -49.11% -45.62%

Does the media refer more to IVVD or JBIO?

In the previous week, Invivyd and Invivyd both had 1 articles in the media. Invivyd's average media sentiment score of 0.67 beat Jade Biosciences' score of 0.00 indicating that Invivyd is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Invivyd 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Jade Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Invivyd (IVVD) Competitors

$0.92 -0.04 (-4.24%)

Closing price 04:00 PM Eastern

Extended Trading

$0.92 +0.00 (+0.21%)

As of 07:55 PM Eastern

Compare

IVVD vs. SVRA, ODTX, MNKD, MLTX, and JBIO

Should you buy Invivyd stock or one of its competitors? Invivyd's main competitors and comparable companies include Savara (SVRA), Odyssey Therapeutics (ODTX), MannKind (MNKD), MoonLake Immunotherapeutics (MLTX), and Jade Biosciences (JBIO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Invivyd compare to Savara?

Savara (NASDAQ:SVRA) and Invivyd (NASDAQ:IVVD) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, profitability, analyst recommendations, institutional ownership, valuation and dividends.

87.9% of Savara shares are owned by institutional investors. Comparatively, 70.4% of Invivyd shares are owned by institutional investors. 5.3% of Savara shares are owned by insiders. Comparatively, 12.3% of Invivyd shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Savara presently has a consensus target price of $10.00, indicating a potential upside of 100.00%. Invivyd has a consensus target price of $8.00, indicating a potential upside of 766.65%. Given Invivyd's higher possible upside, analysts plainly believe Invivyd is more favorable than Savara.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Invivyd	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Invivyd has higher revenue and earnings than Savara. Savara is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Savara	N/A	N/A	-$118.84M	-$0.58	N/A
Invivyd	$53.43M	5.09	-$52.49M	-$0.33	N/A

In the previous week, Savara and Savara both had 1 articles in the media. Savara's average media sentiment score of 1.02 beat Invivyd's score of 0.67 indicating that Savara is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Savara	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Invivyd	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Savara has a net margin of 0.00% compared to Invivyd's net margin of -183.90%. Invivyd's return on equity of -59.73% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Savara	N/A	-90.28%	-68.95%
Invivyd	-183.90%	-59.73%	-48.97%

Savara has a beta of 0.25, indicating that its share price is 75% less volatile than the broader market. Comparatively, Invivyd has a beta of 0.81, indicating that its share price is 19% less volatile than the broader market.

Summary

Invivyd beats Savara on 8 of the 14 factors compared between the two stocks.

How does Invivyd compare to Odyssey Therapeutics?

Invivyd (NASDAQ:IVVD) and Odyssey Therapeutics (NASDAQ:ODTX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

Odyssey Therapeutics has a net margin of 0.00% compared to Invivyd's net margin of -183.90%. Odyssey Therapeutics' return on equity of 0.00% beat Invivyd's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Invivyd	-183.90%	-59.73%	-48.97%
Odyssey Therapeutics	N/A	N/A	N/A

Invivyd presently has a consensus price target of $8.00, suggesting a potential upside of 766.65%. Odyssey Therapeutics has a consensus price target of $35.75, suggesting a potential upside of 72.21%. Given Invivyd's higher possible upside, equities analysts plainly believe Invivyd is more favorable than Odyssey Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Invivyd	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Odyssey Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Odyssey Therapeutics has lower revenue, but higher earnings than Invivyd. Odyssey Therapeutics is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Invivyd	$53.43M	5.09	-$52.49M	-$0.33	N/A
Odyssey Therapeutics	N/A	N/A	N/A	-$6.77	N/A

In the previous week, Invivyd had 1 more articles in the media than Odyssey Therapeutics. MarketBeat recorded 1 mentions for Invivyd and 0 mentions for Odyssey Therapeutics. Invivyd's average media sentiment score of 0.67 beat Odyssey Therapeutics' score of 0.00 indicating that Invivyd is being referred to more favorably in the media.

Company	Overall Sentiment
Invivyd	Positive
Odyssey Therapeutics	Neutral

70.4% of Invivyd shares are held by institutional investors. 12.3% of Invivyd shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Invivyd beats Odyssey Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Invivyd compare to MannKind?

MannKind (NASDAQ:MNKD) and Invivyd (NASDAQ:IVVD) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

MannKind has a beta of 1.1, suggesting that its stock price is 10% more volatile than the broader market. Comparatively, Invivyd has a beta of 0.81, suggesting that its stock price is 19% less volatile than the broader market.

49.6% of MannKind shares are held by institutional investors. Comparatively, 70.4% of Invivyd shares are held by institutional investors. 2.6% of MannKind shares are held by company insiders. Comparatively, 12.3% of Invivyd shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

MannKind has a net margin of -11.08% compared to Invivyd's net margin of -183.90%. MannKind's return on equity of -11.21% beat Invivyd's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MannKind	-11.08%	-11.21%	-6.31%
Invivyd	-183.90%	-59.73%	-48.97%

MannKind presently has a consensus price target of $8.34, suggesting a potential upside of 149.81%. Invivyd has a consensus price target of $8.00, suggesting a potential upside of 766.65%. Given Invivyd's higher probable upside, analysts clearly believe Invivyd is more favorable than MannKind.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MannKind	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
Invivyd	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

MannKind has higher revenue and earnings than Invivyd. MannKind is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MannKind	$348.97M	3.08	$5.86M	-$0.13	N/A
Invivyd	$53.43M	5.09	-$52.49M	-$0.33	N/A

In the previous week, MannKind had 4 more articles in the media than Invivyd. MarketBeat recorded 5 mentions for MannKind and 1 mentions for Invivyd. Invivyd's average media sentiment score of 0.67 beat MannKind's score of 0.60 indicating that Invivyd is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MannKind	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Invivyd	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

MannKind beats Invivyd on 10 of the 15 factors compared between the two stocks.

How does Invivyd compare to MoonLake Immunotherapeutics?

Invivyd (NASDAQ:IVVD) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, media sentiment, dividends, earnings and risk.

MoonLake Immunotherapeutics has a net margin of 0.00% compared to Invivyd's net margin of -183.90%. Invivyd's return on equity of -59.73% beat MoonLake Immunotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Invivyd	-183.90%	-59.73%	-48.97%
MoonLake Immunotherapeutics	N/A	-82.53%	-58.17%

Invivyd presently has a consensus price target of $8.00, suggesting a potential upside of 766.65%. MoonLake Immunotherapeutics has a consensus price target of $24.57, suggesting a potential upside of 90.48%. Given Invivyd's higher possible upside, equities research analysts clearly believe Invivyd is more favorable than MoonLake Immunotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Invivyd	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.44

Invivyd has higher revenue and earnings than MoonLake Immunotherapeutics. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Invivyd	$53.43M	5.09	-$52.49M	-$0.33	N/A
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.84	N/A

70.4% of Invivyd shares are owned by institutional investors. Comparatively, 93.9% of MoonLake Immunotherapeutics shares are owned by institutional investors. 12.3% of Invivyd shares are owned by insiders. Comparatively, 10.4% of MoonLake Immunotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Invivyd has a beta of 0.81, indicating that its share price is 19% less volatile than the broader market. Comparatively, MoonLake Immunotherapeutics has a beta of 1.04, indicating that its share price is 4% more volatile than the broader market.

In the previous week, MoonLake Immunotherapeutics had 1 more articles in the media than Invivyd. MarketBeat recorded 2 mentions for MoonLake Immunotherapeutics and 1 mentions for Invivyd. Invivyd's average media sentiment score of 0.67 equaled MoonLake Immunotherapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Invivyd	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MoonLake Immunotherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Invivyd beats MoonLake Immunotherapeutics on 7 of the 13 factors compared between the two stocks.

How does Invivyd compare to Jade Biosciences?

Invivyd (NASDAQ:IVVD) and Jade Biosciences (NASDAQ:JBIO) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, media sentiment, analyst recommendations, risk, profitability and earnings.

Jade Biosciences has a net margin of 0.00% compared to Invivyd's net margin of -183.90%. Jade Biosciences' return on equity of -49.11% beat Invivyd's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Invivyd	-183.90%	-59.73%	-48.97%
Jade Biosciences	N/A	-49.11%	-45.62%

Invivyd has higher revenue and earnings than Jade Biosciences. Jade Biosciences is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Invivyd	$53.43M	5.09	-$52.49M	-$0.33	N/A
Jade Biosciences	N/A	N/A	-$127.41M	-$1.92	N/A

In the previous week, Invivyd and Invivyd both had 1 articles in the media. Invivyd's average media sentiment score of 0.67 beat Jade Biosciences' score of 0.00 indicating that Invivyd is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Invivyd	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Jade Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Invivyd has a beta of 0.81, indicating that its stock price is 19% less volatile than the broader market. Comparatively, Jade Biosciences has a beta of 1.45, indicating that its stock price is 45% more volatile than the broader market.

70.4% of Invivyd shares are owned by institutional investors. 12.3% of Invivyd shares are owned by insiders. Comparatively, 23.1% of Jade Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Invivyd currently has a consensus target price of $8.00, indicating a potential upside of 766.65%. Jade Biosciences has a consensus target price of $51.75, indicating a potential upside of 251.80%. Given Invivyd's higher possible upside, analysts plainly believe Invivyd is more favorable than Jade Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Invivyd	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Jade Biosciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90

Summary

Jade Biosciences beats Invivyd on 8 of the 14 factors compared between the two stocks.

Get Invivyd News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IVVD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IVVD vs. The Competition

Export

Metric	Invivyd	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$284.15M	$3.90B	$7.21B	$13.10B
Dividend Yield	N/A	3.64%	2.53%	13.00%
P/E Ratio	N/A	13.95	274.58	25.69
Price / Sales	5.09	1,357.85	639.38	80.65
Price / Cash	N/A	109.50	76.31	52.02
Price / Book	0.89	15.30	10.44	6.32
Net Income	-$52.49M	-$22.82M	$3.49B	$359.73M
7 Day Performance	14.63%	-0.22%	0.51%	1.35%
1 Month Performance	-7.37%	-6.06%	-3.38%	-3.68%
1 Year Performance	-20.42%	34.37%	16.04%	5.56%

Invivyd Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IVVD Invivyd	3.703 of 5 stars	$0.92 -4.2%	$8.00 +766.6%	-21.0%	$284.15M	$53.43M	N/A	122
SVRA Savara	2.0797 of 5 stars	$5.41 -0.7%	$10.00 +84.8%	+51.9%	$1.12B	N/A	N/A	70	Positive News
ODTX Odyssey Therapeutics	2.402 of 5 stars	$23.06 flat	$35.75 +55.0%	N/A	$1.11B	N/A	N/A	100
MNKD MannKind	2.8237 of 5 stars	$3.41 -2.7%	$8.34 +145.0%	-37.3%	$1.10B	$393.63M	N/A	592
MLTX MoonLake Immunotherapeutics	2.3354 of 5 stars	$12.62 +0.6%	$24.57 +94.6%	-75.7%	$1.09B	N/A	N/A	130

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IVVD) was last updated on 9/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Invivyd (IVVD) Competitors

IVVD vs. SVRA, ODTX, MNKD, MLTX, and JBIO

How does Invivyd compare to Savara?

Summary

How does Invivyd compare to Odyssey Therapeutics?

Summary

How does Invivyd compare to MannKind?

Summary

How does Invivyd compare to MoonLake Immunotherapeutics?

Summary

How does Invivyd compare to Jade Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IVVD vs. The Competition

Invivyd Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Invivyd (IVVD) Competitors

IVVD vs. SVRA, ODTX, MNKD, MLTX, and JBIO

How does Invivyd compare to Savara?

Do insiders and institutionals believe in SVRA or IVVD?

Do analysts recommend SVRA or IVVD?

Which has higher valuation & earnings, SVRA or IVVD?

Does the media prefer SVRA or IVVD?

Is SVRA or IVVD more profitable?

Which has more risk and volatility, SVRA or IVVD?

Summary

How does Invivyd compare to Odyssey Therapeutics?

Is IVVD or ODTX more profitable?

Do analysts recommend IVVD or ODTX?

Which has higher valuation & earnings, IVVD or ODTX?

Does the media prefer IVVD or ODTX?

Do insiders & institutionals hold more shares of IVVD or ODTX?

Summary

How does Invivyd compare to MannKind?

Which has more risk and volatility, MNKD or IVVD?

Do insiders and institutionals have more ownership in MNKD or IVVD?

Is MNKD or IVVD more profitable?

Do analysts recommend MNKD or IVVD?

Which has better earnings and valuation, MNKD or IVVD?

Does the media prefer MNKD or IVVD?

Summary

How does Invivyd compare to MoonLake Immunotherapeutics?

Is IVVD or MLTX more profitable?

Do analysts rate IVVD or MLTX?

Which has stronger earnings and valuation, IVVD or MLTX?

Do institutionals and insiders hold more shares of IVVD or MLTX?

Which has more risk and volatility, IVVD or MLTX?

Does the media favor IVVD or MLTX?

Summary

How does Invivyd compare to Jade Biosciences?

Is IVVD or JBIO more profitable?

Which has higher earnings and valuation, IVVD or JBIO?

Does the media refer more to IVVD or JBIO?

Which has more risk & volatility, IVVD or JBIO?

Do institutionals & insiders believe in IVVD or JBIO?

Do analysts rate IVVD or JBIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IVVD vs. The Competition

Invivyd Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools